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A B S T R A C T
Osteosarcoma (OS) is the most common primary malignant tumor of bone and the third most common cancer
in childhood and adolescence. However, controversy concerning the ideal combination of chemotherapy agents
ensued throughout the last quarter of the 20th century because of conﬂicting and often nonrandomized data.
Collaborative eﬀorts to increase understanding of the biology of osteosarcoma and the use of preclinical models
to test novel protein targets will be critical to identify the path toward improving outcomes for patients. We
attempted to identify potential protein markers or therapy targets of osteosarcoma and give a glance at
tumorigenesis of osteosarcoma. A sensitive and accurate method was employed in comparative proteomic
analysis between benign tumor and osteosarcoma. Tumor tissues obtained by open biopsy before induction
chemotherapy were investigated With 2D DIGE and MALDI-TOF/TOF MS, 22 diﬀerentially expressed proteins
were identiﬁed after database searching, including 8 up-regulated and 14 down-regulated proteins. We also
validated the expression levels of interesting proteins(have higher Ratios(tumor/normal)) by Western blotting
assay. Annotating by bioinformatic tools, we found structural and signal transduction associated proteins were
in large percentage among altered level proteins. In particular, some low abundant proteins involving
translation and transcription, such as EEF2(Elongation Factor 2), LUM Lumican 23 kDa Protein) and
GTF2A2(Transcription Initiation Factor Iia Gamma Chain.), were ﬁrstly reported by our study comparing to
previous observations. Our ﬁndings suggest that these diﬀerential proteins may be potential biomarkers for
diagnosis or molecules for understanding of osteosarcoma tumorigenesis, coming with biologic, preclinical, and
clinical trial eﬀorts being described to improve outcomes for patients.
1. Introduction
Osteosarcoma (OS) is the most common primary malignant bone
sarcoma, which usually occurring in children and adolescents [1].
Actually, OS comprises approximately 1/5 of all bone tumors, which is
the ﬁfth most common type of cancer in young people [2–4]. At
present, despite modern treatment protocols that combine chemother-
apy and surgery, the optimal schedule of therapy is still being
investigated because of high recurrence and drug-resistance [5].
Osteosarcoma is pathologically deﬁned by production of osteoid [6],
but it is broadly characterized by genetic complexity caused by
chromosomal alternations [7]. Perhaps, the most attractive data
potentially indicating pathogenesis of osteosarcoma is germ-line ge-
netic alternations. It was reported that germ-line mutations in Rb gene
is correlated to OS [8,9]. In fact, a large number of animal models are
developed for osteosarcoma, including P53 knock out mouse model
[10], transgenic c-fos mouse model [11] and parathyroid hormone
injection mouse model [12]. But it is still unclear which model could
accurately recapitulate the human disease.
There is a real need to identify signaling molecules and mechanisms
that promote OS progression and metastasis, particularly for the
development of novel and more eﬀective treatment strategies.
Since the advent of genomics technology, proteomics provides a
powerful tool to discover new biomarkers for early diagnosis [13] . It
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has been reported that there are vast of genes and proteins expression
changes, involved in biochemical pathways, occurred in tumorigenesis
[14,15]. So far, several proteomics researches of osteosarcoma have
been established base on serum, cell lines and tissues treated by
chemotherapy [16–18]. According to these studies, the expression of
SAA, Fibrinogen, AHA1, SLP-2 and EZR was signiﬁcantly changed. The
most extensively studied prognostic marker is p-glycoprotein encoded
by multi-drug resistance (MDR1) gene [19], but its eﬃcacy remains
controversial [20]. These proteins may be considered as potential
molecular targets for therapy of osteosarcoma. However, there are few
reports directly concerning primary bone sarcoma tissues with high-
through and sensitive methods. Hence, it needs urgently to uncover
robust and speciﬁc markers for understanding the biological behavior
of osteosarcoma.
In this study, clinical tissues from osteosarcoma were analyzed by
2D DIGE and MALDI-TOF/TOF MS. With sensitive labeling method,
some low expression proteins were identiﬁed, which play important
roles in signal transduction pathways. Many diﬀerent kinds of struc-
tural proteins were also detected ﬁrstly in our study comparing to
previous research. More importantly, combination of our result and
previous proteome data, discovery of speciﬁc bio-marker for clinical
diagnosis is promising.
2. Materials and methods
2.1. Patients and tissues specimens
Primary tumor samples, including benign tumors and osteosarco-
mas, were obtained when patients underwent surgery for tumor
resection. According to World Health Organization (WHO) histologic
classiﬁcation, 6 patients were diagnosed with an osteoblastic variant of
osteosarcoma and two had a chondroblastic variant of osteosarcoma.
The benign bone tumors collected included two osteoblastoma, two
chondroblastoma, and one giant cell tumor of bone collected from
patients ranging from 9 to 41 years old.
Fig. 1. the comparison of 2D-DIGE of normal and osteosarcomas tissue.
Table 1.
Differential proteins identified by 2D-DIGE.
Up-regulated proteins
IPIAccession Gene_name Ratio(tumor/normal) Definition
IPI00440493 ATP5A1 1.52 ATP synthase subunit alpha, Mitochondrial precursor.
IPI00298497 FGB 2.17 Fibrinogen beta chain precursor.
IPI00025363 GFAP 2.24 Isoform 1 of glial fibrillary acidic protein, Astrocyte .
IPI00410714 HBA1 2.63 Hemoglobin subunit alpha.
IPI00853068 HBA2 1.61 Hemoglobin Alpha-2.
IPI00654755 HBB 3.09 Hemoglobin subunit beta.
IPI00794403 LUM 1.53 LUM 23 kDa protein.
IPI00006114 SERPINF1 3.58 Pigment epithelium-derived factor precursor.
Down-regulated proteins
IPIAccession Gene_name Ratio(tumor/normal) Definition
IPI00894365 ACTB −1.53 cDNA FLJ52842, highly similar to actin, Cytoplasmic 1.
IPI00186290 EEF2 −1.88 Elongation factor 2.
IPI00465248 ENO1 −1.57 Enolase 1.
IPI00011454 GANAB −1.75 Isoform 2 Of neutral alpha-glucosidase Ab precursor.
IPI00004353 GTF2A2 −1.7 Transcription initiation factor lia gamma chain.
IPI00003865 HSPA8 −2.37 Isoform 1 of heat shock cognate 71 kDa protein.
IPI00784154 HSP60 −1.68 60 kDa heat shock protein, Mitochondrial precursor.
IPI00220327 KRT1 −1.57 Keratin, Type II cytoskeletal 1.
IPI00789173 LDHB −2.07 LDHB_HUMAN L-lactate dehydrogenase B chain
IPI00514204 LMNA −2.3 Lamin A/C
IPI00872814 MOES −2.13 Moesin
IPI00479185 TPM3 −1.95 Tropomyosin 3 Isoform 4
IPI00027107 TUFM −1.58 Tu translation elongation factor, Mitochondrial
IPI00418471 VIM −2.12 Vimentin
G. Wang et al. Journal of Bone Oncology 5 (2016) 147–152
148
2.2. Reagents and apparatus
Cy2, Cy3, and Cy5 were purchased from GE Healthcare. dimethyl-
formamide was purchased from Aldrich. DTT, urea, agarose, glycerol,
bromphenol blue, CHAPS, mineral oil, acrylamide, Bis, Tris base,
glycine, SDS, iodoacetamide, ammonium persulfate, TEMED,
Immobiline DryStrip gels (24 cm, pH 3–10), and Bio-Lyte solutions
(pH 3–10) were purchased from Bio-Rad. Thiourea was purchased
from Fluka (Buchs, Switzerland). Protease inhibitor mixture was
purchased from Roche Applied Science. ACN and methanol were
purchased from Fisher. TFA was purchased from Merck. Trypsin
(sequencing grade) was purchased from Promega (Madison, WI). All
buﬀers were prepared with Milli-Q water (Millipore, Bedford, MA).
2.3. Protein extraction
The tumor tissues were crushed in a liquid nitrogen cooled mortar
and pestle, and then extracted with 300 ml sample buﬀer containing
7 M urea, 2 M thiourea and 4% CHAPS,. The lysate was separated by
centrifugation at top speed for 30 min at 4 °C. The supernatant was
collected and stored at −80 °C.
2.4. 2D-DIGE and image analysis
Protein extraction concentration was determined by BCA method
and pH was adjusted to 8.5 by 50 mM NaOH. After that, the
concentration was made to 5 mg/ml by lysis buﬀer. Equal amounts
of proteins from the 6 pairs of samples were pooled together as the
internal standard. Benign and osteosarcoma tissue were randomly
labeled with Cy3 or Cy5, whereas internal standards were labeled with
Cy2 using 400 pmol of ﬂuorochrome/50 g of protein. Labeling was
performed for 30 min on ice in the dark.
Reactions were then stopped by the addition of 1 μl of lysine
(10 mM) for 10 min on ice in the dark. Fifty-microgram Cy3- and Cy5-
labeled samples from each group were combined before mixing with
50 μg of Cy2-labeled internal standard. Then an equal volume of 2 μl
sample buﬀer (7 M urea, 2 M thiourea, 4% CHAPS, 1% Bio-Lyte, pH 3–
10, 20 mg/ml DTT) was added to the sample, and the total volume was
made up to 450 μl with rehydration buﬀer (7 M urea, 2 M thiourea, 4%
CHAPS, 0.5% Bio-Lyte, 10 mg/ml DTT).
Samples were actively rehydrated into 24-cm pH 3–10 IPG strips
(Bio-Rad) at 17 °C for 7 h using a Protean IEF cell (Bio-Rad).
Isoelectric focusing was performed for a total of 80 kV-h, involving in
desalting (250 V in 30 min), boosting voltage (held at 1000 V for 1 h,
ramped to 10,000 V in 5 h) and holding (10,000 V for 70 kV-h). The
IPG strips were equilibrated in equilibration buﬀer (6 M urea, 2% SDS,
50 mM Tris-Cl, pH 8.8, 30% glycerol) supplemented with 0.5% DTT for
15 min at room temperature followed by 4.5% iodoacetamide in
equilibration buﬀer for another 15-min incubation at room tempera-
ture.
IPG strips were placed on the top of 12% homogeneous polyacry-
lamide gels that had been precast with low ﬂuorescence glass plates
using an Ettan DALT twelve gel caster. The second dimension SDS-
PAGE was carried out using the Protean Plus system (Bio-Rad). After
2DE, gels were scanned on the Typhoon 9410 scanner with Ettan DALT
gel alignment guides using excitation/emission wavelengths speciﬁc for
Cy2 (488/520 nm), Cy3 (532/580 nm), and Cy5 (633/670 nm). The
intensity was adjusted to ensure that the maximum volume of each
image was within 60,000–90,000.
2.5. Data analysis
All experiments were carried out in triplicate; Analysis of 2D DIGE
was done using DeCyder 5.02 software (GE Healthcare) according to
the manufacturer’s suggestion. Brieﬂy, the DeCyder biological variation
analysis module was used to detect spots (the estimated number of
spots was 2500) and simultaneously match all 49 protein spot maps
from 3 gels. All matches were also conﬁrmed by manual. Diﬀerent
density of protein spots among benign tumor and osteosarcoma were
marked. Only spots that variation was more than 2.0 were selected for
identiﬁcation. Spot picking and in-gel Digestion was carried out with
preparative gels. Two-dimensional electrophoresis was performed as
described under “2D DIGE and Imaging” except that the IPG strips
were loaded with 500–1000 μg of protein, and gels were stained with
Coomassie Brilliant Blue. Protein spots of interest were excised and
destained with 25 mM ammonium bicarbonate in 50% ACN. Gels were
then dried completely by centrifugal lyophilization. In-gel digestion
was performed with 0.01 μg/μl trypsin (Promega) in 25 mM ammo-
nium bicarbonate for 15 h at 37 °C. The supernatants were collected,
and the tryptic peptides were extracted from the gel sequentially with
Fig. 2. Validation of diﬀerentially expressed proteins by Western blotting assay.
Fig. 3. Function distribution of diﬀerential protein between normal and tumor tissue.
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5% TFA at 40 °C for 1 h and with 2.5% TFA, 50% ACN at 30 °C for 1 h.
The extracts were pooled and dried completely by centrifugal lyophi-
lization.
2.6. Protein identiﬁcation by MALDI-TOF/TOF MS
Peptide mixtures were dissolved in 0.5% TFA, and 1 μl of peptide
solution was mixed with 1 μl of matrix (4-hydroxy-α-cyanocinnamic
acid in 30% ACN, 0.1% TFA) before spotting on the target plate. PMF
and sequence analysis were carried out on a MALDI-TOF-TOF MS
(4800 Proteomics Analyzer, Applied Biosystems). Peptide mass maps
were acquired in positive reﬂection mode, averaging 1500 laser shots
per MALDI-TOF spectrum and 3000 shots per TOF/TOF spectrum (the
resolution was 20,000). The 4800 calibration mixtures (Applied
Biosystems) were used to calibrate the spectrum to a mass tolerance
within 0.1 Da. Parent mass peaks with a mass range of 600–4000 Da
and minimum signal to noise ratio of 15 were picked out for tandem
TOF/TOF analysis. Combined mass and mass/mass spectra were used
to interrogate human sequences IPI human database using the
MASCOT database search algorithms (version 1.9). In Searching
parameter, modiﬁcation was set as carbamidomethylation, oxidation,
and a maximum of one missed trypsin cleavage was permitted.
Tolerance of precursor and fragment ions was both 0.2 Da. All of the
automatic data analysis and database searching were fulﬁlled by the
GPS ExplorerTM software (version 3.6, Applied Biosystems).
Contaminant proteins, such as keratin (from skin or hair), were
excluded manually. The conﬁdent identiﬁcation had a statistically
signiﬁcant (p≤0.05) protein score (based on combined mass and
mass/mass spectra) and best ion score (based on mass/mass spectra).
Redundancy of proteins that appeared in the database under diﬀerent
names and accession numbers was eliminated. If more than one
protein was identiﬁed in one spot, the single protein member with
the highest protein score (top rank) was singled out from the protein
family. The molecular weight and pI values of most proteins were
consistent with the gel regions from which the spots were excised.
2.7. Western blot assay
Proteins from the benign tumors and osteosarcoma were separated
on 12% polyacrylamide gels and transferred to PVDF membranes
(Amersham Biosciences). These blots were incubated for 2 h at room
temperature in Tris-buﬀered-saline with Tween (20 mM Tris-Cl,
140 mM NaCl, pH 7.5, 0.05% Tween 20) containing 5% skim milk.
Primary antibodies used were anti-glial ﬁbrillary acidic protein mono-
clonal antibody (diluted 1:200, Promega), anti-pigment epithelium-
derived factor (diluted 1:500 Sigma), anti-heat shock cognate 71 kDa
protein (diluted 1:1000 Sigma) and anti-Lamin A/C (diluted 1:500
Santa Cruze). Blots were incubated with primary antibodies for 2 h at
room temperature. After washing three times in Tris-buﬀered-saline
with Tween, blots were incubated with horseradish peroxidase-con-
jugated secondary antibody (diluted 1:10,000, Santa Cruz
Biotechnology) for 1 h at room temperature. Immunoreactive com-
plexes were visualized using ECL reagents (Santa Cruz Biotechnology).
3. Results
3.1. Comparison of diﬀerentially expressed proteins between
osteosarcoma and benign tumor
After labeling and electrophoresis, the Cy2, Cy3, and Cy5 channels
of each gel were imaged separately, and the images were analyzed using
DeCyder 5.02 software. Among 1600 matched protein spots, 11 were
signiﬁcantly up-regulated and 15 were down-regulated in comparison
between benign tumors and osteosarcoma ratio of which was set to 2.0
(spots shown in Fig. 1).
3.2. Analysis of diﬀerential proteome by mass spectrometry
In total, 25 diﬀerently expressed spots were excised from gels and
analyzed for protein identiﬁcation with the MALDI-TOF/TOF mass
spectrometer. After searching database, 8 up-regulated proteins were
identiﬁed, including ﬁbrinogen beta chain (FGB), glial ﬁbrillary acidic
protein (GFAP), hemoglobin subunit alpha (HBA1), hemoglobin sub-
unit beta (HBB), pigment epithelium derived factor (SERPINF1), ATP
synthase subunit alpha (ATP5A1), LUM 23 kDa protein (LUM) and
hemoglobin alpha-2 (HBA2)(Table 1). While, 14 down-regulated
proteins were detected, namely heat shock cognate 71 kDa protein
(HSPA8), lamin A/C (LMNA), moesin (MOES), vimentin (VIM), L-
lactate dehydrogenase B (LDHB), tropomyosin 3 (TPM3), elongation
factor 2 (EEF2), neutral alpha-glucosidase Ab (GANAB), transcription
initiation factor IIA (GTF2A2), 60 kDa heat shock protein (HSPD1), Tu
translation elongation factor (TUFM), type II keratin (KRT1), enolase 1
(ENO1) and actin, cytoplasmic 1 (ACTB) (Table 1).
As for up-regulated proteins, some spots appeared to be detected as
the same protein. For example, spots 542 and 631 were SERPINF1,
while spots 1054 and 1154 corresponded to ATP5A1 (Fig. 1).
3.3. Western blotting assay
Two up-regulated proteins of interest, GFAP and SERPINF1, as
well as two down-regulated proteins, LMNA and HSPA8 were selected
for further validation by Western blotting assay. According to Fig. 2,
the changes of these proteins between benign tumors and osteosarco-
ma were consistent with proteomic data.
3.4. Function analysis of diﬀerentially expressed proteins
To investigate the function of diﬀerentially expressed proteins,
Gene Ontology was employed for annotating the results. Consequently,
some functional factors were classiﬁed, including carbohydrate meta-
bolism, structural maintenance, stress response, signal transduction,
transport and so on (Fig. 3). Among these categories, more than 1/3
proteins were related to cellular structure and proteins involving in
signal transduction were also in large percentage.
4. Discussion
One of the major challenges in treatment of osteosarcoma is lack of
validated prognostic markers. By standard clinical treatment, the
recurrent rate of patients received surgical operation and chemother-
apy is near about 1/3 [21]. In post genome, proteomics serves as
powerful tools in screening marker and targets, especially employed in
cancer research. In this study, we identiﬁed 14 up-regulated proteins
and 8 down-regulated proteins in osteosarcoma, including metabolic
proteins, cytoskeletal proteins, and signal transmitting proteins.
4.1. Structural proteins in osteosarcoma
In organisms, structural proteins are widely distributed and play a
role in celluar maintenance. We indentiﬁed structural proteins, includ-
ing GFAP, KRT1, LMNA, TPM3, VIM and MOES. GFAP is a member of
intermediary ﬁlament protein family, which is an important compo-
nent of astrocytes and a known diagnostic marker of glial diﬀerentia-
tion. By Q-PCR and immunohistochemistry, GFAP was found to be
highly expressed in chondrosarcomas and chondroblastic osteosarco-
mas [22]. It was implicated a potential marker for tumors with
cartilaginous diﬀerentiation. As for moesin, it is a member of the
ERM (ezrin, radixin, moesin) protein family and connects major
cytoskeletal structures to the plasma membrane. It has been proved
that ERM is activated by phosphorylation in OS [23] and ezrin, another
member of ERM, is believed to involve in matastatsis in osteosarcoma
[24]. It is suggested that ezrin and, potentially, other members of the
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ERM (ezrin-radixin-moesin) family have key roles in the coordination
of signals and cellular complexes that are required for the successful
metastasis of these and other malignancies [24]. Vimentin is class-III
intermediate ﬁlament, and its expression is elevated when oxidative
phosphorylation is reduced in osteosarcoma [25].
4.2. Proteins involving in signal transduction
According to GO annotation, 4 genes were related to signal
transduction, EEF2, FGB, LUM and TUFM. Fibrinogen is a pleiotropic
blood protein that regulates coagulation, inﬂammation and tissue
repair. In microglia, ﬁbrinogen mediates activation of Akt and Rho
via the CD11b/CD18 integrin receptor, while in neurons ﬁbrinogen
induces phosphorylation of epidermal growth factor (EGF) receptor via
the alphavbeta3 integrin [26]. Lumican is a member of small eucine-
rich proteoglycan gene family and is known to play a role in the
assembly and regulation of collagen ﬁbres [27]. In human osteosarco-
ma cell lines, it was demonstrated that lumican had a novel out-in
signaling circuit that inhibited endogenous TGF-β2 activity, resulting
in downstream eﬀector modulation including pSmad 2, integrin β1 and
pFAK to regulate osteosarcoma adhesion [28]. Another study of
lumican showed its potential correlation with the diﬀerentiation and
progression of osteosarcoma [29]. EEF2 is a component of the mRNA
surveillance SURF complex and catalyzes the GTP-dependent riboso-
mal translocation step during translation elongation. It was reported
that EEF1A1, an isoform of EEF, was over expressed in osteosarcoma
and showed chemo-sensitization toward MTX by treatment with siRNA
[30]. In our result, EEF2 had an opposite expression regulation pattern
to EEF1A1. As for TUFM, there is no report of its relationship with
osteosarcoma.
4.3. Heat shock proteins down-regulated in osteosarcomas
Heat shock proteins (HSPs) are a kind of molecular chaperones and
protect cells against injuries form stress. HSPA8 and HSP60 were
identiﬁed in our experiment, and both of these two proteins were down
regulated. By previous study on clinical samples, HSP27, HSP60, and
HSP70 were determined and found HSP27 and HSP70 may be
potential markers to distinguish conventional and low grade central
osteosarcoma [31,32]. HSPA8 may function as an endogenous inhibi-
tory regulator of HSC70 by competing to the co-chaperones. The eﬀect
of HSPA8 was ﬁrstly reported in ostosarcoma by our research.
4.4. Comparison with other published proteome of osteosarcoma
At present, there are several proteomic studies of osteosarcoma,
including serum, tissues and cell lines [18–20]. To give a survey of
biological behavior of OS, we incorporated these datasets and com-
pared it to our result at gene level (Table 1). From the table, the overlap
among identiﬁcations was small, which suggested proteins were
diﬀerentially expressed in tissues/ﬂuids. Comparing to published data,
several low abundant proteins related to signal transduction and
transcription, such as EEF2, LUM and GTF2A2, were uncovered for
the ﬁrst time. These proteins may help to understand the regulation of
osteosarcoma.
5. Conclusion
In this study, the proteins diﬀerentially expressed in osteosarcoma
were analyzed by high sensitive labeling method and mass spectro-
metry. Although some proteins were accordant with previous reports,
but many proteins had been identiﬁed and validated in osteosarcoma at
ﬁrst. In particular, the identiﬁcation of structural and signal transduc-
tion associated proteins implied that these proteins play an important
role in the process of tumorigenesis and metastasis in osteosarcoma.
The identiﬁed uniquely expressed proteins comparing to literature may
be valuable to elucidate the regulation mechanism of osteosarcoma, as
well as provide potential markers or targets for diagnosis and therapy.
Of course, the exact eﬀect of these molecules still unclear, so additional
work is required to give an answer to the role of these proteins in
osteosarcoma genesis.
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